Immunovant Provides Update on Graves' Disease Development Program

2 weeks ago

NEW YORK, Sept. 09, 2024 ( GLOBE NEWSWIRE ) -- Immunovant, Inc. ( Nasdaq: IMVT ) , a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported positive results from the Phase 2a trial of batoclimab in Graves' Disease.

Ticker	Sentiment	Impact
IMVT	Somewhat Bullish	69 %